BioCentury
ARTICLE | Clinical News

Azeliragon: Phase III started

June 1, 2015 7:00 AM UTC

vTv (formerly TransTech Pharma LLC) began the double-blind, placebo-controlled, North American Phase III trial to evaluate 5 mg oral azeliragon once daily for 18 months in about 800 patients receivin...